JP2020023567A5 - - Google Patents

Download PDF

Info

Publication number
JP2020023567A5
JP2020023567A5 JP2019194647A JP2019194647A JP2020023567A5 JP 2020023567 A5 JP2020023567 A5 JP 2020023567A5 JP 2019194647 A JP2019194647 A JP 2019194647A JP 2019194647 A JP2019194647 A JP 2019194647A JP 2020023567 A5 JP2020023567 A5 JP 2020023567A5
Authority
JP
Japan
Prior art keywords
xaa
absent
amino acid
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019194647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020023567A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020023567A publication Critical patent/JP2020023567A/ja
Publication of JP2020023567A5 publication Critical patent/JP2020023567A5/ja
Pending legal-status Critical Current

Links

JP2019194647A 2013-06-28 2019-10-25 アミノ酸及びペプチド接合体及び接合方法 Pending JP2020023567A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ612654 2013-06-28
NZ61265413 2013-06-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016522936A Division JP6659535B2 (ja) 2013-06-28 2014-06-27 アミノ酸及びペプチド接合体及び接合方法

Publications (2)

Publication Number Publication Date
JP2020023567A JP2020023567A (ja) 2020-02-13
JP2020023567A5 true JP2020023567A5 (enExample) 2020-03-26

Family

ID=52142779

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016522936A Expired - Fee Related JP6659535B2 (ja) 2013-06-28 2014-06-27 アミノ酸及びペプチド接合体及び接合方法
JP2019194647A Pending JP2020023567A (ja) 2013-06-28 2019-10-25 アミノ酸及びペプチド接合体及び接合方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016522936A Expired - Fee Related JP6659535B2 (ja) 2013-06-28 2014-06-27 アミノ酸及びペプチド接合体及び接合方法

Country Status (8)

Country Link
US (2) US10576144B2 (enExample)
EP (2) EP3604271A1 (enExample)
JP (2) JP6659535B2 (enExample)
CN (2) CN105555756B (enExample)
AU (3) AU2014300503B2 (enExample)
CA (1) CA2953747A1 (enExample)
TW (2) TWI655201B (enExample)
WO (1) WO2014207708A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2811957C (en) 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
TW201735952A (zh) * 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
EP3676250A4 (en) * 2017-08-30 2021-05-26 Auckland Uniservices Limited PEPTIDE CONJUGATES, CONJUGATION METHODS AND USES THEREOF
US20200353088A1 (en) * 2017-11-06 2020-11-12 Auckland Uniservices Limited Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof
IL275360B2 (en) 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds
MX2020009950A (es) * 2018-03-23 2021-04-28 Carmot Therapeutics Inc Moduladores de receptores acoplados a proteina g.
US12522644B2 (en) 2019-03-04 2026-01-13 University Health Network T cell receptors and methods of use thereof
MX2021010537A (es) 2019-03-04 2021-12-10 Univ Health Network Receptores de linfocitos t y metodos de uso de estos.
AU2020231693A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
AU2020231927A1 (en) * 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
CA3133945A1 (en) 2019-03-25 2020-10-01 University Health Network T cell receptors and methods of use thereof
NZ783377A (en) 2019-06-26 2026-03-27 Ena Respiratory Pty Ltd Pegylated novel molecules for agonising tlr2
EP4141110A4 (en) 2020-04-24 2025-04-09 Sf Biotech Laboratuvar Danismanlik Anonim Sirketi Method for producing particles of bacteriophages of the genus levivirus
CN111921001A (zh) * 2020-08-19 2020-11-13 兰州百源基因技术有限公司 一种用于伤口愈合的薄膜及其制备方法
KR20240007251A (ko) 2021-05-13 2024-01-16 카모트 테라퓨틱스, 인크. G-단백질 결합 수용체의 조절제
EP4488283A1 (en) * 2022-04-08 2025-01-08 Chugai Seiyaku Kabushiki Kaisha Production method for peptide compound

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4939240A (en) 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
DE3813821A1 (de) 1988-04-22 1989-11-02 Hoechst Ag Synthetische vakzine gegen die maul- und klauenseuche und verfahren zu deren herstellung
US6074650A (en) 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US4743543A (en) 1985-09-09 1988-05-10 Coulter Corporation Method for enhancing and/or accelerating immunoassay detection of human carcinoma tumor associated antigen in a pathology sample
US4921790A (en) 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
US5053489A (en) 1988-01-29 1991-10-01 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4914021A (en) 1988-03-04 1990-04-03 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US4921789A (en) 1988-04-20 1990-05-01 New England Deaconess Hospital Corporation Marker for colorectal carcinoma and methods of detecting the same
JPH02172946A (ja) 1988-12-26 1990-07-04 Shinetsu Sakusan Vinyl Kk カルボン酸アルケニルエステルの製造方法
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
CA2117477C (en) 1992-12-11 2001-06-12 Peter S. Mezes Multivalent single chain antibodies
AU6102494A (en) 1993-02-05 1994-08-29 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
US6310180B1 (en) 1993-06-21 2001-10-30 Vanderbilt University Method for synthesis of proteins
DE4331011A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik
AUPM446594A0 (en) 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
JPH08248579A (ja) 1995-03-14 1996-09-27 Mitsubishi Paper Mills Ltd ハロゲン化銀写真感光材料及びその処理方法
US5994294A (en) 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
US6251603B1 (en) * 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
US6982085B2 (en) 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
DE69837273T2 (de) * 1997-10-08 2008-01-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
PT1147117E (pt) 1999-02-01 2004-10-29 Eisai Co Ltd Compostos adjuvantes imunologicos
WO2001055393A2 (en) 2000-01-28 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
AU2001273639A1 (en) 2000-06-26 2002-01-08 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
US6506875B1 (en) 2000-09-26 2003-01-14 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-C molecules and uses thereof
GB0030067D0 (en) 2000-12-11 2001-01-24 Univ Bristol Therapeutic agent
EP1229043A1 (en) 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
AU2002353485B2 (en) 2001-12-04 2009-01-15 Ben Gurion University Of The Negev Research And Development Authority Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
FR2836684B1 (fr) * 2002-03-04 2004-12-17 Inst Nat Sante Rech Med Peptides ras mutes et leur utilisation en immunotherapie
AU2003274463B2 (en) 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
GB0214528D0 (en) 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
WO2004006952A2 (en) 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
US7569225B2 (en) 2002-08-12 2009-08-04 The Council Of The Queensland Institute Of Medical Research Immunogenic lipopeptides comprising T-helper and B-cell epitopes
ES2535451T3 (es) 2002-08-12 2015-05-11 The Council Of The Queensland Institute Of Medical Research Nuevos lipopéptidos inmunógenos que comprenden epítopos de linfocitos T auxiliares y de linfocitos T citotóxicos (CTL)
WO2004041849A1 (en) 2002-11-07 2004-05-21 The Council Of The Queensland Institute Of Medical Research Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
US20080139464A1 (en) * 2003-05-30 2008-06-12 Ludwig Institute Of Cancer Research Isolated Ny-Eso-1 Peptides Which Bind To Hla Class II Molecules And Uses Thereof
US20070197541A1 (en) 2003-07-29 2007-08-23 Oyelere Adegboyega K Biaryl heterocyclic amines,amides, and sulfur-containing compounds and methods of making and using the same
AU2005285513B2 (en) 2004-05-25 2011-02-24 Oregon Health And Science University SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
EP1666056A1 (en) 2004-12-06 2006-06-07 Bestewil Holding B.V. Cancer vaccine vesicles
EP1850832B1 (en) 2005-02-07 2014-12-31 Lipotek PTY Ltd Adjuvanting material
FR2881746B1 (fr) 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
EP1861426A4 (en) 2005-02-08 2008-11-12 Queensland Inst Med Res IMMUNOGENOUS MOLECULES
GB0507003D0 (en) * 2005-04-06 2005-05-11 Molmed Spa Therapeutic
CA2616906A1 (en) 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
US8357373B2 (en) * 2005-10-04 2013-01-22 Ludwig Institute For Cancer Research Methods for stimulating an immune response using bacterial antigen delivery system
EP1933834A1 (en) 2005-10-12 2008-06-25 Biolipox AB Benzoxazoles useful in the treatment of inflammation
JP4824389B2 (ja) 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性t細胞エピトープペプチド及びその用途
EP1963358A4 (en) 2005-12-06 2009-03-25 Univ Australian TREATMENT OF DISEASES ASSOCIATED WITH THE EPSTEIN-BARR-VIRUS
WO2007078879A2 (en) 2005-12-21 2007-07-12 Vaxinnate Corporation Lipopeptide compositions and methods of use thereof
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
WO2008021296A2 (en) 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of alzheimer's disease
EP2118128B1 (en) 2007-01-15 2012-11-07 GlaxoSmithKline Biologicals SA Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
US8309096B2 (en) * 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
EP3533461A3 (en) 2007-03-26 2019-12-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Prame derived peptides and immunogenic compositions comprising these
WO2008151197A2 (en) 2007-06-04 2008-12-11 The Regents Of The University Of California Tumor-derived endogenous toll-like receptor 4 ligands
US20110262473A1 (en) 2008-07-07 2011-10-27 The University Of Melbourne Synthetic vaccine component
US20100266623A1 (en) 2008-07-07 2010-10-21 The University Of Melbourne Synthetic, self adjuvanting vaccines
US20110171259A1 (en) * 2008-09-05 2011-07-14 Martin Gagne Novel Compositions and Adjuvants
US8436015B2 (en) 2008-09-15 2013-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2011063233A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
US8822485B2 (en) 2009-11-23 2014-09-02 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011109237A2 (en) 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap
US10238734B2 (en) 2010-03-23 2019-03-26 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US20130029358A1 (en) 2010-04-01 2013-01-31 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
WO2011156686A2 (en) 2010-06-11 2011-12-15 The Regents Of The University Of Colorado, A Body Corporate Method for synthesizing a cyclic multivalent peptide using a thiol-mediated reaction
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
EP2608806B1 (en) 2010-08-25 2017-10-25 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) An epstein-barr-virus vaccine
US20140086888A1 (en) 2010-09-01 2014-03-27 Helen E. Heslop Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc)
BR112013005970A2 (pt) 2010-09-14 2016-07-05 Council Scient Ind Res imunógeno sintético, últil para gerar imunidade duradoura e proteção contra patógenos.
ES2635335T3 (es) 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
CA2811957C (en) 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
WO2012069188A1 (en) 2010-11-24 2012-05-31 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V Continuous flow processes for photoconjugation of high-molecular chemical entities
US9187534B2 (en) * 2011-03-11 2015-11-17 Universite De Geneve Multi-epitopic vaccine
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
US9309278B2 (en) 2011-05-13 2016-04-12 Nanyang Technological University Method for modification of organic molecules
US20120328660A1 (en) 2011-06-03 2012-12-27 Tsuji Takemasa Immunogenic compositions useful in provoking an integrated response to tumor antigens
CN102839186A (zh) * 2011-06-21 2012-12-26 上海生物制品研究所有限责任公司 表达ny-eso-1重组耻垢分枝杆菌的制备及应用
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
WO2013036543A2 (en) * 2011-09-10 2013-03-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging of cancer cells in vivo
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
IN2014CN02581A (enExample) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
US9056141B2 (en) 2012-05-31 2015-06-16 Synchem, Inc. Thiol-ene click chemistry for drug conjugates
US9861702B2 (en) 2012-10-22 2018-01-09 Wisconsin Alumni Research Foundation Lipid-conjugated rhamnose for immune system recruitment and oncotherapy
JP6548579B2 (ja) * 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程

Similar Documents

Publication Publication Date Title
JP2010500399A5 (enExample)
JP2012500001A5 (enExample)
CA2187083C (fr) Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation
US11666630B2 (en) Polypeptides for managing viral infections
FI3642340T3 (fi) Muunneltu l-asparaginaasi
JP2019533722A5 (enExample)
JP2008529558A5 (enExample)
JP2005516885A5 (enExample)
JP2022513223A5 (enExample)
JP2018506286A5 (enExample)
JP2014521684A5 (enExample)
JP2006506942A5 (enExample)
JPWO2019107530A5 (enExample)
JP2018515101A5 (enExample)
JP2011523857A5 (enExample)
JP2020536489A5 (enExample)
JP2020518287A5 (enExample)
JP2014529399A5 (enExample)
JP2020117504A5 (enExample)
CN109535232B (zh) 多肽、其制备方法及抑制艾滋病病毒的用途
JP2020509770A5 (enExample)
JP2020515283A5 (enExample)
JP2018533908A5 (enExample)
JP2019534242A5 (enExample)
JP2009544304A5 (enExample)